CPMD · Cannapharmarx, Inc. · Analyst Estimates
Substantial doubt about the company's ability to continue as a going concern.
“Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
One customer — 63% of revenue (the year ended December 31, 2025)
“During the year ended December 31, 2025, the Company also recognized revenue of $861,476 (2024 - $nil) from the sale of cannabis products to a pharmaceutical company based in Germany. This comprised 63% of the revenues generated during the year ended December 31, 2025.”
One customer — 29% of revenue (the year ended December 31, 2025)
“During the year ended December 31, 2025, the Company recognized revenue of $394,633 (2024 - $770,265) from Cantek (Note 12), which was 29% of the total revenue (2024 - 94%).”
Analyst Estimates
Compare analyst forecasts for Cannapharmarx, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Published by the company
Only independently verified consensus published through the company's investor-relations sources is available.
Consensus not yet available
Only independently verified consensus published through the company's investor-relations sources is available.